articleThe Lancet OncologySep 25, 2017Closed access

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

YWYi‐Long WuYCYing ChengXZXiangdong ZhouKHKi Hyeong LeeKNKazuhiko Nakagawa

Guangdong Academy of Medical Sciences · Guangdong General Hospital · +12 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,200
total citations
FWCI
82.87
Percentile
100%
References
32
Citations per year

Authors

18

Topics & keywords

Topics
Keywords
  • Medicine
  • Gefitinib
  • Internal medicine
  • Clinical endpoint
  • Discontinuation
  • Oncology
  • Lung cancer
  • Population
No related works found for this paper.

Funding